medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-11-50-53medsovet-1146Research ArticleБронхиальная астмаBronchial asthmaВопросы неотложной терапии бронхообструктивных заболеваний в амбулаторной практикеEmergency treatment of broncial obstruction diseases in outpatient practiceЛещенкоИ. В.LeschenkoI. V.noemail@neicon.ruГБОУ ВПО «Уральский государственный медицинский университет» Минздрава России, ЕкатеринбургРоссияUral State Medical University, Russia's Ministry of Health, YekaterinburgRussian Federation2013301220130115053Copyright © Лещенко И.В., 20132013Лещенко И.В.Leschenko I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1146

К наиболее часто встречающимся бронхообструктивным заболеваниям относятся бронхиальная астма (БА) и хроническая обструктивная болезнь легких (ХОБЛ). Как правило, обострение БА и ХОБЛ сопровождается острым бронхообструктивным синдромом (БОС). Хорошо известно, что при оказании неотложной помощи больным с острым БОС препаратами первого ряда являются бронхолитические средства короткого действия и глюкокортикоиды. Бронхолитические препараты короткого действия назначаются при обострении, угрозе развития обострений или в качестве симптоматической терапии при БА и ХОБЛ и отражают наряду с клинико-функциональными признаками течение заболеваний (контролируемая, частично контролируемая, неконтролируемая БА) [1].

The most widespread bronchial obstruction diseases are bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD). Exacerbations of asthma and COPD are typically accompanied by acute bronchial obstruction syndrome (BOS). It is common knowledge that first-line drugs in the emergency care of patients with acute BOS are short-acting bronchodilators and glucocorticoids. Short-acting bronchodilators are used in the treatment of exacerbations, to prevent risk of exacerbation or as a symptomatic treatment of BA and COPD, in accordance with clinical and functional symptoms and the course of the disease (controlled, partly controlled, uncontrolled BA) [1] .

бронхообструктивные заболеваниябронхолитические препараты-агонистдозирующие аэрозольные ингаляторыbronchial obstruction diseasesbronchodilatorsshort-acting β2-agonistmetered-dose inhalerReferencesGlobal Strategy for Asthma Management and Prevention, Workshop Report (updated 2011). www.ginashtma. org.Global Strategy for Asthma Management and Prevention, Workshop Report (updated 2011). www.ginashtma. org.Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2011).Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2011).Show M. 2-agonists, from pharmacological properties to everyday clinical practice. International workshop report (based on a workshop held in London, UK Feb. 28–29, 2002).Show M. 2-agonists, from pharmacological properties to everyday clinical practice. International workshop report (based on a workshop held in London, UK Feb. 28–29, 2002).Bremmer P., Woodman K., Burgess C. et al. Comparison of cardiotoxicity and the effect on metabolism formoterol, salbutamol and fenoterol // Eur. Respir. J., Feb. 1993.Bremmer P., Woodman K., Burgess C. et al. Comparison of cardiotoxicity and the effect on metabolism formoterol, salbutamol and fenoterol // Eur. Respir. J., Feb. 1993.Lipwor B.J., Newnham D.M., Clarc R.A. Comparison of dose-dependent effect on airway and systemic effects of salbutamol and fenoterol in patients with asthma // Тhorax. 1995. №50. Р. 54–61.Lipwor B.J., Newnham D.M., Clarc R.A. Comparison of dose-dependent effect on airway and systemic effects of salbutamol and fenoterol in patients with asthma // Тhorax. 1995. №50. Р. 54–61.Hockley B., Johnson N. Fenoterol versus salbutamol nebulization in asthma // Postgraduate Medical Journal. 1983. №59. Р. 504–505.Hockley B., Johnson N. Fenoterol versus salbutamol nebulization in asthma // Postgraduate Medical Journal. 1983. №59. Р. 504–505.Lipwor D.J., Newtham D.M., Clark R.A. et al. Comparison of dose-dependent effect on airway and systemic effects of salbutamol and fenoterol in patients with asthma // Thorax. 1995. №50. Р. 54–61.Lipwor D.J., Newtham D.M., Clark R.A. et al. Comparison of dose-dependent effect on airway and systemic effects of salbutamol and fenoterol in patients with asthma // Thorax. 1995. №50. Р. 54–61.Bellamy D., Penketh A.A. A cumulative dose comparison between salbutamol and fenoterol metered dose aerosols in asthmatic patients // Postgraduate Medical Journal. 1987. №63. Р. 459–461.Bellamy D., Penketh A.A. A cumulative dose comparison between salbutamol and fenoterol metered dose aerosols in asthmatic patients // Postgraduate Medical Journal. 1987. №63. Р. 459–461.Show M. β2-agonists pharmacological properties to everyday clinical practice. International workshop repot. London. 2002. Р. 28–29Show M. β2-agonists pharmacological properties to everyday clinical practice. International workshop repot. London. 2002. Р. 28–29Bremmer P., Woodman K., Burgess C. et al. Comparison of cardiotoxicity and the effect on metabolism formoterol, salbutamol and fenoterol // Eur. Respir. J., Feb. 1993.Bremmer P., Woodman K., Burgess C. et al. Comparison of cardiotoxicity and the effect on metabolism formoterol, salbutamol and fenoterol // Eur. Respir. J., Feb. 1993.Lipwor B.J., Newnham D.M., Clarc R.A. Comparison of dose-dependent effect on airway and systemic effects of salbutamol and fenoterol in patients with asthma // Тhorax. 1995. №50. Р. 54–61.Lipwor B.J., Newnham D.M., Clarc R.A. Comparison of dose-dependent effect on airway and systemic effects of salbutamol and fenoterol in patients with asthma // Тhorax. 1995. №50. Р. 54–61.Hockley B., Johnson N. Fenoterol versus salbutamol nebulization in asthma // Postgraduate Medical Journal. 1983. №59. Р. 504–505.Hockley B., Johnson N. Fenoterol versus salbutamol nebulization in asthma // Postgraduate Medical Journal. 1983. №59. Р. 504–505.Lipwor D.J., Newtham D.M., Clark R.A. et al. Comparison of dose-dependent effect on airway and systemic effects of salbutamol and fenoterol in patients with asthma // Thorax. 1995. №50. Р. 54–61.Lipwor D.J., Newtham D.M., Clark R.A. et al. Comparison of dose-dependent effect on airway and systemic effects of salbutamol and fenoterol in patients with asthma // Thorax. 1995. №50. Р. 54–61.Bellamy D., Penketh A.A. A cumulative dose comparison between salbutamol and fenoterol metered dose aerosols in asthmatic patients // Postgraduate Medical Journal. 1987. №63. Р. 459–461.Bellamy D., Penketh A.A. A cumulative dose comparison between salbutamol and fenoterol metered dose aerosols in asthmatic patients // Postgraduate Medical Journal. 1987. №63. Р. 459–461.Show M. β2-agonists pharmacological properties to everyday clinical practice. International workshop repot. London. 2002. Р. 28–29.Show M. β2-agonists pharmacological properties to everyday clinical practice. International workshop repot. London. 2002. Р. 28–29.Hockley B., Jonson N. Fenoterol versus salbutamol nebulization in asthma // Postgraduate Medical Journal. 1983. №59. Р. 504–505.Hockley B., Jonson N. Fenoterol versus salbutamol nebulization in asthma // Postgraduate Medical Journal. 1983. №59. Р. 504–505.Bremmer P., Woodman K., Burgess C. et al. Comparison of cardiotoxicity and the effect on metabolism fenoterol, salbutamol // Eur. Respir. J. 1993. №32. Р. 106–111.Bremmer P., Woodman K., Burgess C. et al. Comparison of cardiotoxicity and the effect on metabolism fenoterol, salbutamol // Eur. Respir. J. 1993. №32. Р. 106–111.Сelli B.R., MacNee W., and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS-position paper // Eur. Respir. J. 2004. №23 (6). Р. 932–946.Сelli B.R., MacNee W., and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS-position paper // Eur. Respir. J. 2004. №23 (6). Р. 932–946.Thompson J., Irvine T., Grathwohl K. et al. Misuse of meter-dose inhalers // Chest. 1994. №105. Р. 715–717.Thompson J., Irvine T., Grathwohl K. et al. Misuse of meter-dose inhalers // Chest. 1994. №105. Р. 715–717.Lenney J., Innes J.A., Crompton G.K. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices // Resp. Med. 2000. №94. Р. 496–500.Lenney J., Innes J.A., Crompton G.K. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices // Resp. Med. 2000. №94. Р. 496–500.Anhoj J., Bisgaard H., Lipwort B.J. Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children // Brit. J. Clin. Pharmacol. 1999. №47. Р. 333–336.Anhoj J., Bisgaard H., Lipwort B.J. Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children // Brit. J. Clin. Pharmacol. 1999. №47. Р. 333–336.Chrystyn H. The Discus inhaler. A review of its pharmaceutical and clinical performance // Clin. Drug Invest. 1999. №18. Р. 403–412.Chrystyn H. The Discus inhaler. A review of its pharmaceutical and clinical performance // Clin. Drug Invest. 1999. №18. Р. 403–412.Borgstom L.E., Bondesson F., Moren E. еt al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subject // Eur. Respir. J. 1994. №7. Р. 69–73.Borgstom L.E., Bondesson F., Moren E. еt al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subject // Eur. Respir. J. 1994. №7. Р. 69–73.O’Donohue, and the National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. Guidelines for the use of nebulizers in the home and at domiciliary sites // Chest. 1996. №109. Р. 14.O’Donohue, and the National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. Guidelines for the use of nebulizers in the home and at domiciliary sites // Chest. 1996. №109. Р. 14.

The authors declare that there are no conflicts of interest present.